Studies related to Pain and Serrapeptase

Evaluation Of Serratia Peptidase In Acute Or Chronic Inflammation Of Otorhinolaryngology Pathology: A Multicentre, Double-blind, Randomized Trial Versus Placebo

Effect Decrease
Trial Design Double blind
Trial Length 1-2 Weeks
Number of Subjects 193
Gender Both Genders
Age Range 18-29, 30-44, 45-64, 65+
Notes for this study:
In persons with acute or chronic ear, nose or throat disorders given 10mg of serrapeptase thrice daily (30mg total), supplementation was more effective than placebo in reducing abnormalities of mucus production and swallowing and was also analgesic.

Comparison Of The Roles Of Serratiopeptidase And Dexamethasone In The Control Of Inflammation And Trismus Following Impacted Third Molar Surgery

Effect Decrease
Trial Design Double blind
Trial Length 1-7 Days
Number of Subjects 110
Gender Both Genders
Age Range 18-29, 30-44, 45-64, 65+
Body Types Overweight, Average
Notes for this study:
In patients undergoing jaw surgery (removal of third molar), 30mg serrapeptase daily for up to a week was more effective than placebo in reducing pain and swelling although trismus (opening of the jaw) was unaffected.

Clinical Study Of The Efficacy Of And Tolerance To Seaprose S In Inflammatory Venous Disease. Controlled Study Versus Serratio-peptidase

Effect Decrease
Trial Design Cohort
Trial Length 1-2 Weeks
Number of Subjects 40
Gender Both Genders
Age Range 30-44, 45-64, 65+
Body Types Average
Notes for this study:
In persons with superficial thrombophlebitis given 30mg serrapeptase (10mg thrice daily) relative to the comparator drug Protease S (Seaprose S; no placebo control in this study) noted that both drugs were able to reduce pain and symptoms of thrombophlebitis, but the symptoms alleviation seen with serrapeptase (65%) was outperformed by protease S (85%).

The Treatment Of Breast Engorgement With Serrapeptase (Danzen): A Randomised Double-blind Controlled Trial

Effect Decrease
Trial Design Double blind
Trial Length 1-7 Days
Number of Subjects 70
Gender Female
Age Range 18-29, 30-44
Body Types Average
Notes for this study:
10mg serrapeptase thrice daily (30mg total) for 3 days in women with breast engorgement was able to reduce pain and tenderness as assessed by self-report surveys.

A Randomized, Double-blind, Placebo-controlled Study Comparing The Efficacy And Safety Of Paracetamol, Serratiopeptidase, Ibuprofen And Betamethasone Using The Dental Impaction Pain Model

Effect None
Trial Design Double blind
Trial Length 1-7 Days
Number of Subjects 150
Gender Both Genders
Age Range 18-29, 30-44, 45-64
Body Types Overweight, Average
Notes for this study:
Relative to the comparator drugs (betamethasone and paracetamol), serrapeptase was less effective in reducing pain and inflammation associated with third molar surgery when taken at the standard 30mg dosage; relative to placebo, there was no significant difference.